“Green light” to Lilly’s monoclonal antibody to migraine

2018-11-28T17:21:25+00:0028/11/2018|Categories: Industry, News|Tags: , , , , , , , |

Eli Lilly announces that the European Commission (EC) has approved the commercialization of galcanezumab ( Emgality ) as a prophylactic treatment of migraine in adults suffering from at least four days of migraine per month . Galcanezumab is a humanized monoclonal antibody that binds to the peptide related to the calcite gene (CGRP, for its acronym in English) associated with episodes of migraine, blocks its function Administered with a month subcutaneous injection which can be applied to the patient with a pen or pre-filled syringe. In all three clinical trials, galcanezumab has shown significantly reducing the monthly average of migraine days and an improvement in functionality versus placebo. "Migraine is [...]

We and our partners use cookies, to collect browsing data to give you the best online experience and to personalize the content, play multimedia content, interact with social networks and perform browsing analytics. If you continue browsing we understand you accept the use of such technology. For more information visit our cookies policy Find out more

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close